[
    [
        {
            "time": "",
            "original_text": "贝达药业（300558.SZ）：盐酸恩沙替尼一线治疗适应症药品注册申请纳入优先审评审批程序",
            "features": {
                "keywords": [
                    "贝达药业",
                    "盐酸恩沙替尼",
                    "一线治疗",
                    "药品注册",
                    "优先审评",
                    "审批程序"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "贝达药业（300558.SZ）：盐酸恩沙替尼一线治疗适应症药品注册申请纳入优先审评审批程序",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        }
    ]
]